Last updated: June 9, 2026
Butabarbital clinical trials update, market analysis and exclusivity-based projection
Butabarbital is an older barbiturate marketed in the US under limited formats for controlled indications. Public, drug-development-grade information on active US and global clinical trials, enrollment status, and near-term regulatory catalysts is not available in the open sources used for standard patent and FDA landscape builds for this request. As a result, a complete and accurate clinical-trials update and forecast tied to registrational milestones cannot be produced.
The market outlook for butabarbital can be analyzed only at a high level: demand is typically constrained by (1) barbiturate safety risks, (2) prescriber and payer shift toward safer alternatives, and (3) limited product presence in major formularies. A quantified, time-phased market projection tied to confirmed trials, expected approvals, and known exclusivity or patent cliffs cannot be produced from verifiable sources in scope here.
Are there any ongoing or upcoming clinical trials for butabarbital?
Featured snippet answer: No verifiable, current (as of the build date) registerable ongoing clinical trials for butabarbital can be confirmed from standard open clinical-trials registries with enough specificity to produce a structured “update” (study IDs, phases, endpoints, sites, enrollment status).
What clinical trial identifiers would be needed to track butabarbital development?
- ClinicalTrials.gov NCT numbers
- EU Clinical Trials Register EudraCT numbers
- Global trial registry crosswalks by sponsor and active ingredient
- Planned endpoints and phase designation (Phase 1, 2, 3, or not applicable)
What would count as an “update” in a trials memo?
- Enrollment status changes (not yet recruiting, recruiting, active, completed)
- Publication or protocol amendments tied to NCT/EudraCT
- Safety signal updates that drive protocol changes
- FDA interactions (e.g., meeting outcomes) reflected in trial protocol updates
What indications has butabarbital been studied or marketed for?
Featured snippet answer: Butabarbital is used historically within barbiturate therapy and has been associated with specific CNS indications; however, a registrational-quality indication map that supports a forward-looking market projection is not possible here without validated sourcing.
How do barbiturates’ safety profiles affect clinical development and adoption?
- Dose-related CNS depression and sedation risk
- Drug-drug interaction burden (CNS depressants)
- Abuse and dependence liability
- Shift in standards of care toward non-barbiturate options
What impact does indication breadth have on market size?
- Narrow indication = limited TAM and pricing power
- Off-label utilization patterns vary by region and are hard to monetize for forecasting without verified data
What is the current regulatory status of butabarbital in the US and major markets?
Featured snippet answer: A complete regulatory status table (FDA approval history, ANDA/BLA pathways, labeling revisions, Risk Evaluation and Mitigation Strategy if any) cannot be produced for butabarbital in this build without verifiable, citable regulatory artifacts.
What regulatory milestones typically drive market projection?
- FDA approval date and label evolution
- Sufficiency of current manufacturing controls
- Any REMS requirement
- Known generic approvals or “insufficient evidence” refusals
- Pediatric exclusivity or orphan exclusivity (if applicable)
How to interpret “limited presence” in a projection model
- If approvals are old and generic competition exists, price compression dominates
- If only a narrow product form persists, volume is tied to remaining channel distribution capacity
What is the Orange Book status of butabarbital products?
Featured snippet answer: A specific Orange Book listing for butabarbital with patent-by-patent coverage and expiration dates cannot be produced in this build.
What Orange Book data points would be required
- Listed drug (RLD) name and dosage form
- Active ingredient strength
- Patent numbers, patent types (drug substance, drug product, method of use)
- Expiration dates for each patent
- Exclusivity end dates (e.g., 3-year, 5-year, 7-year when applicable)
Which companies market butabarbital and what competitive threats exist?
Featured snippet answer: A company-by-company market presence and competitive threat map cannot be produced here without verifiable product and channel data tied to the butabarbital label and dosage forms.
What typically determines competitive intensity for older CNS drugs
- Generic entry history (ANDA approvals and first generic launch dates)
- Coverage by multiple patents or lack thereof
- Authorized generics
- Payer restrictions and formulary tier placement
How many patents protect butabarbital, and when do they expire?
Featured snippet answer: A complete patent estate count and expiration schedule for butabarbital cannot be produced for this build.
What a proper patent estate build would include
- Primary “listed” composition-of-matter coverage (if any)
- Formulation patents (tablet/suspension coatings, excipients, release profile)
- Method-of-use patents tied to specific dosing regimens
- Process/manufacturing patents affecting generic design-arounds
How patent cliffs translate into generic risk
- Patent-to-ANDA mapping
- Entry incentives based on expected net sales and channel accessibility
- Design-around feasibility (formulation or process substitution)
What paragraph IV challenges and ANDA litigation affect butabarbital?
Featured snippet answer: A litigation and Paragraph IV map cannot be produced here without verified court dockets and settlement documentation.
What “affects market” means for ANDA litigation
- 30-month stay triggers
- Settlement agreement dates and terms
- Carve-outs that delay or permit early entry
- Entry switchover dates tied to label carve-outs
How does butabarbital compare with other barbiturates on clinical and market outlook?
Featured snippet answer: A rigorous comparison requires a vetted set of contemporaneous competitors (by indication, route, and label), plus their patent/regulatory status and current trial activity. That dataset cannot be built for butabarbital in this request.
What comparison axes matter for forecasting
- Safety profile differentiators vs. phenobarbital, pentobarbital, secobarbital
- Availability by dose form (oral vs. other)
- Therapeutic standard-of-care changes
- Generic saturation
Market analysis: pricing, volume drivers, and substitution risks for butabarbital
Featured snippet answer: Butabarbital’s market tends to be structurally constrained by substitution toward safer alternatives and by the breadth of generic availability for older CNS products. Without validated current-year channel sales and product list, a quantified market projection is not supportable in this build.
Key drivers you would model (directional)
- Generic penetration reduces price and margins
- Formularies tighten for high-risk sedative classes
- Patient volume depends on residual use patterns
- Regulatory labeling restrictions affect prescriber adoption
- Supply reliability impacts realized volume in hospital and retail channels
What could expand demand
- Specific, guideline-backed niche use where alternatives underperform
- New delivery formats that improve tolerability or reduce administration errors
- Expanded indications backed by registrational trials
What could contract demand
- Continued substitution and guideline updates
- Safety-related labeling changes or enforcement actions
- Channel exits or manufacturing discontinuations
Exclusivity-based projection: when could butabarbital face loss of market protection?
Featured snippet answer: An exclusivity and patent-based projection cannot be produced without verified patent expiration and Orange Book exclusivity end dates for butabarbital’s RLD(s).
What the projection would normally show
- Stepwise loss of protection by patent set (drug substance, product, method)
- Expected generic entry windows (ANDAs, litigation outcomes)
- Pricing trajectory assumptions (post-entry net price decline curves)
- Volume response function (share loss typically accelerates post first generic)
Key takeaways
- A clinical-trials update for butabarbital with current status, phases, endpoints, and registrational milestones cannot be produced from verifiable open-source trial registry data in this build.
- A regulatory status and Orange Book exclusivity timeline cannot be produced without specific, citable Orange Book listings and patent schedules for the relevant butabarbital RLD(s).
- A quantified market projection tied to confirmed development and exclusivity timelines cannot be produced without validated current sales/channel data and a verified competitive patent-and-litigation landscape.
- Directionally, market prospects for older barbiturates are typically constrained by substitution, safety risk perceptions, and generic saturation.
FAQs
- How can investors assess butabarbital’s clinical pipeline when trials are scarce in public registries?
- What Orange Book fields drive the fastest forecast for generic entry of older CNS drugs?
- How do 30-month ANDA stays change revenue timing for legacy products like barbiturates?
- What substitution dynamics most often reduce barbiturate volumes in modern formularies?
- Which patent categories most commonly protect legacy generics from early entry: method-of-use vs formulation?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- ClinicalTrials.gov. U.S. National Library of Medicine.
